Welcome to Novo Nordisk in the United States


Why Measurement Matters

There are often gaps in information and research on chronic disease, and by filling these gaps, we can advance sound public policy decisions. We want to understand the challenges people living with diabetes face on a daily basis, which is why we’re conducting and commissioning research that helps describe and measure these problems and challenges.

 

The Future of Diabetes1

We commissioned and worked with the Institute for Alternative Futures (IAF) to conduct research that was the first to provide detailed diabetes prevalence (including demographics) and individual cost forecasts for all 50 states. Compared with a baseline in 2015, it was estimated that the overall number of people in the United States living with diabetes will increase 54% by 2030 to 54.9 million. The resulting medical and societal cost of diabetes will be almost $623 billion—a 53% increase from 2015.

Learn more

 

DAWN 2

Our DAWN2 (Diabetes Attitudes, Wishes and Needs) initiative is a global partnership focused on advancing patient-centered diabetes care, and represents the voice of more than 15,000 people who are living with diabetes, family members of people with diabetes, and health care providers.

Learn More

 

Cost of Diabetes2

Every five years Novo Nordisk has been commissioning research to understand the total cost of all types of diabetes and prediabetes. The study found that the total cost of diabetes and prediabetes rose 48% over the 5-year period from 2007-2012, growing from $218 to $322 billion for both medical expenditures and reduced productivity.

Learn More

 

Diabetes Medication Adherence3

Novo Nordisk commissioned this research to estimate the level of diabetes medication adherence to antidiabetic agents, diabetes control, and their association among patients with T2DM receiving medication treatment. The study, published in the Journal of Managed Care & Specialty Pharmacy, showed that more than one-third of all insured patients with diagnosed type 2 diabetes did not fill their diabetes medication regularly and at least 40% of all insured patients with type 2 diabetes did not have their disease under control.

Learn More

 

ACTION Study4

The "Awareness, Care and Treatment In Obesity Management" (ACTION) Study is the first U.S. nationwide study to investigate barriers to obesity management from the perspective of people with obesity, health care professionals and employers. In addition, the study aims to generate insights to guide collaborative action to improve obesity care, education and support. Sponsored by Novo Nordisk, the ACTION Study was led by a multi-disciplinary steering committee comprised of representatives from The Obesity Society, the Obesity Action Coalition, and the Integrated Benefits Institute, as well as obesity experts in the fields of primary care, endocrinology, psychology and nursing. The study involved more than 3,000 people with obesity, 600 health care professionals, and 150 employers in the United States.

Learn More

 

 


References:

  1. Rowley, William R. et al. “Diabetes 2030: Insights from Yesterday, Today, and Future Trends." Population Health Management 20.1 (2017): 6–12.
  2. Dall, Timothy M., et al. “The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes.” Diabetes Care, vol. 37, no. 12, 2014, pp. 3172–3179.
  3. Tan, Eleonora, et al. “Geographic Variation in Antidiabetic Agent Adherence and Glycemic Control Among Patients with Type 2 Diabetes.” Journal of Managed Care & Specialty Pharmacy, vol. 21, no. 12, 2015, pp. 1195–1202.
  4. Kaplan, L. M., Golden, A., Jinnett, K., Kolotkin, R. L., Kyle, T. K., Look, M., Nadglowski, J., O'Neil, P. M., Parry, T., Tomaszewski, K. J., Stevenin, B., Lilleøre, S. K. and Dhurandhar, N. V. (2018), Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study. Obesity, 26: 61-69. doi:10.1002/oby.22054